If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.
about
Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderlyTargeted Therapy of Ewing's Sarcoma.Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cellsAssociations of insulin resistance and adiponectin with mortality in women with breast cancer.Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis.Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion currentGerosuppressant metformin: less is moreHormesis does not make sense except in the light of TOR-driven aging.Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.Tristetraprolin mediates the anti-proliferative effects of metformin in breast cancer cellsMetformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond.Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects.Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials.Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt studyMetformin and cancer: licence to heal?A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer.Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
P2860
Q27025344-4E11C159-C5B5-4A6B-896D-98E4F7D98FA1Q34262377-B2B5FCDE-E7DD-4D9F-802E-1157A7F56DE6Q34293099-8F912A36-62ED-4DE6-A25D-5956FC567624Q34662835-6D67BEA7-6FA5-43C2-9F1C-7714E34987A6Q34662845-B69FCE94-CE6A-4036-99FD-33ED0B32D62DQ34957274-EE4FA758-0F57-4228-9371-EA07A36C709FQ35052060-F5E3BE00-D4E1-4D5E-A616-9C36781D062FQ35645142-D21C0556-F18C-49DF-BA30-588DA361E6CFQ35835794-5223D2CA-298E-40C5-A1DD-D2E021DF5741Q36678490-83852900-F3F6-48B0-AF80-74A49F27FE14Q36896122-1F7F3F68-1E88-4EBD-8C2A-9939EBB6525AQ37783621-44BC6087-0275-4ED7-8B4A-179F92E7CD9FQ38016107-E890392A-6ED6-4284-97F7-0343DBD1B74FQ41339882-B7DB83BC-D857-4832-95A2-C51E2E18D852Q41630845-04B1AAEE-7635-406A-892A-97E281AC13F1Q43015031-F935990E-7FC1-489D-9A4B-2DBB9B51FAB8Q46063551-84914445-57B2-41A6-BD4F-8A905E21341CQ58735770-8259F0DE-E2E1-4811-85B3-4FD778978EE3
P2860
If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
If mammalian target of metform ...... min in cancer clinical trials.
@en
If mammalian target of metform ...... min in cancer clinical trials.
@nl
type
label
If mammalian target of metform ...... min in cancer clinical trials.
@en
If mammalian target of metform ...... min in cancer clinical trials.
@nl
prefLabel
If mammalian target of metform ...... min in cancer clinical trials.
@en
If mammalian target of metform ...... min in cancer clinical trials.
@nl
P2093
P356
P1476
If mammalian target of metform ...... min in cancer clinical trials.
@en
P2093
Alejandro Vazquez-Martin
Cristina Oliveras-Ferraros
Javier A Menendez
Sonia Del Barco
P304
e207-9; author reply e210
P356
10.1200/JCO.2009.24.5456
P407
P577
2009-10-26T00:00:00Z